Molecular basis of human immunodeficiency virus drug resistance: an update.
about
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicCurrent perspectives on HIV-1 antiretroviral drug resistanceViral quasispecies evolutionEvaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug ResistanceCrystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding PocketExtreme Multidrug Resistant HIV-1 Protease with 20 Mutations Is Resistant to Novel Protease Inhibitors with P1′-Pyrrolidinone or P2-Tris-tetrahydrofuranSelective unfolding of one Ribonuclease H domain of HIV reverse transcriptase is linked to homodimer formationEvidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndromeInhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymeraseInhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNAWhich Patient Characteristics Among Cocaine Users with HIV Relate to Drug Use and Adherence Outcomes Following a Dual-Focused Intervention?Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structureA pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users.Recent findings on the mechanisms involved in tenofovir resistance.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.Evolutionary biochemistry: revealing the historical and physical causes of protein properties.Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.The flavivirus protease as a target for drug discovery.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 proteaseGenetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Molecular Basis for Drug Resistance in HIV-1 ProteaseSubtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Emerging paramyxoviruses: molecular mechanisms and antiviral strategiesIdentification of covalent active site inhibitors of dengue virus protease.Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tractNMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities.New insights into HIV assembly and trafficking.Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war.Intergenerational phenotypic mixing in viral evolution.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaMultiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsExtracts from Acacia catechu suppress HIV-1 replication by inhibiting the activities of the viral protease and Tat.
P2860
Q24655011-D43ECE46-37BF-44B3-B10F-EF5294452A2CQ26852626-08951BB0-E720-472C-8CEE-8C53747B44BDQ27013917-5F8BBCA9-7E7B-4591-B85C-A3EF5F979F29Q27660267-64A251B3-F069-44C6-A223-EC278D612CF4Q27667348-C0096F2E-DC43-4A23-8227-954315A82ECDQ27677405-F66A8DE4-91FE-46D1-9E68-63C3CDFB0847Q27681926-69CEC76B-B2A0-41B3-BE43-F9315DA53103Q28304673-DEC4BE57-2FE6-4DF8-8482-1FFEC3779120Q28476610-E1E008C9-48C8-4E40-9C26-F1AEFC3CEEF1Q28478188-AEAF0697-6806-4921-8636-B904EEB1512DQ30279065-50D759AC-3F0B-42A8-99A2-BB1388A7251FQ30365343-751FAC0B-AA5F-4D08-A00D-CD8DF1E387E7Q30426188-E6F2D539-7D8A-4BE3-937B-6E5C5BBAA5E3Q33831709-E3E1C298-A138-4B92-8C9B-6A927B90008DQ33889635-EC0AF79F-D822-4569-8D23-D2F1F1DFB062Q34058254-055BC069-0A73-436C-B905-7B9ACFDA39EBQ34094395-EAAE0731-705D-4807-A63C-4393DE516D22Q34151017-5F1144F6-B5DE-449A-B09A-5792DE700B54Q34358160-010C0F25-DE4F-4532-BE99-EC4A7E9FDB88Q34483487-7DA60148-83E2-438A-BC09-C85CA7611312Q34657530-25FCEFD5-49E5-4997-917E-C500D25A829CQ34754045-E7269857-BAD2-49D9-AB87-2275EAC3BA83Q35022038-7E7789C0-E7B5-450E-8AD7-241B7A888DA5Q35022791-7D496D7D-D367-4B46-88F5-A3D81245F74CQ35260330-DB858E04-D189-4343-9563-E73A0C9E6802Q35260370-F8E89C78-D5D5-4807-9DA9-E2AA74469D8AQ35607740-525A6ADB-2F70-4F8D-B0F4-B47AB2BE393FQ35633587-A9E87167-7DB4-4615-9713-F7BED9A1D1DAQ35658152-78A102D7-EE0C-4B1E-9A97-89BF071C4EEEQ35871359-E3BBC898-F532-4034-A02E-4552DD580710Q36098779-04970B9B-EB44-4D15-811C-5559B66BA4A6Q36221687-C3E07D6F-D0D3-4AA2-89BF-CBD165CE1F18Q36307738-AE02EB7A-6830-4055-85AB-04368D813C35Q36627970-5AA77BED-5712-4896-92B5-2F6B8BBE000AQ36913846-C5706FC0-81E8-4ECF-B57A-43A1DDC4DD25Q36969977-FB22A125-3268-46E5-8B95-2B0333DC0D56Q37033512-C78F0A7E-4551-4587-8719-638F59AB1D13Q37126494-951A6207-6867-4068-9A12-857811AAFA73Q37263541-DA5721E7-E385-4510-A55C-1D6659959ADAQ37285671-0EAD33BB-1BD7-4F83-9137-03AFD4724535
P2860
Molecular basis of human immunodeficiency virus drug resistance: an update.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular basis of human immunodeficiency virus drug resistance: an update.
@en
Molecular basis of human immunodeficiency virus drug resistance: an update.
@nl
type
label
Molecular basis of human immunodeficiency virus drug resistance: an update.
@en
Molecular basis of human immunodeficiency virus drug resistance: an update.
@nl
prefLabel
Molecular basis of human immunodeficiency virus drug resistance: an update.
@en
Molecular basis of human immunodeficiency virus drug resistance: an update.
@nl
P1433
P1476
Molecular basis of human immunodeficiency virus drug resistance: an update
@en
P2093
Luis Menéndez-Arias
P304
P356
10.1016/J.ANTIVIRAL.2009.07.006
P577
2009-07-16T00:00:00Z